Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis

Advances in Therapy

Volumn 23, Issue 6, 2006, Pages 842-853

  Atmaca, Aysegul ^a,b   Gedik, Olcay ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Apartment S106 ^*  (United States)

Author keywords

Alendronate; Bone mineral density; Bone turnover markers; Postmenopausal osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN; PHOSPHATE; RISEDRONIC ACID; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AGING; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG FORMULATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME IMMUNOASSAY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; RADIUS; SINGLE DRUG DOSE; TREATMENT OUTCOME; VERTEBRA;

AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENSITOMETRY, X-RAY; ETIDRONIC ACID; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PROSPECTIVE STUDIES; RADIUS;

EID: 33847361386     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850205     Document Type: Article

References (21)

1. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1991;90:107-110.
2. Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am J Med. 1995;98:3s-8s.
3. Garnero P, Delmas PD. Osteoporosis. Endocrinol Metab Clin North Am. 1997;26:913-936.
4. Garnero P, Sornay-Rendu E, Duboeuf MC, Delmas PD. Markers of bone turnover predict post-menopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res. 1999;14:1614-1621.
5. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture risk in elderly women: the EPIDOS prospective study. J Bone Miner Res. 1996;11:1531-1538.
6. Garnero P, Dargent-Molina P, Hans D, et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int. 1998;8:563-569.
7. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.
8. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
9. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-1443.
10. Reginster J, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91.
11. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
12. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.
13. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin. 2003;19:383-394.
14. Sarioglu M, Tuzun C, Unlu Z, Tikiz C, Taneli F, Uyanik BS. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Rheumatol Int. 2006;26:195-200.
15. Sebba AI, Bonnick SL, Kagan R, et al, for the Fosamax Actonel Comparison Trial (FACT) investigators. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin. 2004;20:2031-2041.
16. Rosen CJ, Hochberg MC, Bonnick SL, et al, for the Fosamax Actonel Comparison Trial investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20:141-151.
17. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83:396-402.
18. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85:1895-1900.
19. Kress BC, Mizrahi IA, Armour KW, Marcus R, Emkey RD, Santora AC 2nd. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women. Clin Chem. 1999;45:1009-1017.
20. Chailurkit L, Ongphiphadhanakul B, Piaseu N, Saetung S, Rajatanavin R. Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory. Clin Chem. 2001;47:1083-1088.
21. Yilmaz N, Bayram M, Erbagci AB, Kilincer MS. Diagnostic value of biochemical markers of bone turnover and postmenopausal osteoporosis. Clin Chem Lab Med. 1999;37:137-143.